Aspirin has been in use over the years for primary prevention of major adverse cardiovascular events (MACE) a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death.
In a metanalysis on comparison of contemporary versus older studies it was noted aspirin had a significant reduction on MACE and a significant increase in the risk of major hemorrhage and intracranial hemorrhage
It was also noted that aspirin has no mortality benefit when used for primary prevention.
Statins use has however reduced the risk of non-fatal MI when used for primary cardiovascular prevention.
All over the world different guidelines are in use on aspirin for primary prevention of cardiovascular events.
In conclusion more, studies need to be done to come up with one guideline on who and when aspirin should be used for primary prevention of MACE, however as for the metanalysis recommendation made was not to use aspirin for primary prevention.
Family Practice, 2019,1_7 doi:10.1093/fampra/cmz080